Bright Minds Biosciences Files Q3 Financials
Ticker: DRUG · Form: 6-K · Filed: Aug 15, 2025 · CIK: 1827401
Sentiment: neutral
Topics: financials, reporting, interim-results
TL;DR
BRIGHT MINDS BIOSCIENCES (DRUG) FILED Q3 FINANCIALS - CHECK THE NUMBERS!
AI Summary
Bright Minds Biosciences Inc. filed a Form 6-K on August 15, 2025, reporting its Condensed Interim Consolidated Financial Statements for the nine months ended June 30, 2025, and 2024, along with its Management's Discussion and Analysis for the Third Quarter Ended June 30, 2025. The company is incorporated in A1 and its fiscal year ends on September 30.
Why It Matters
This filing provides investors with updated financial performance and management insights for Bright Minds Biosciences, crucial for evaluating the company's current health and future prospects.
Risk Assessment
Risk Level: medium — The filing contains financial statements and MD&A, which are standard for public companies but require careful analysis to assess financial health and operational risks.
Key Players & Entities
- Bright Minds Biosciences Inc. (company) — Registrant
- June 30, 2025 (date) — Reporting period end date
- June 30, 2024 (date) — Prior period end date
- August 15, 2025 (date) — Filing date
FAQ
What specific financial results are detailed in the Condensed Interim Consolidated Financial Statements?
The filing incorporates by reference the Condensed Interim Consolidated Financial Statements for the nine months ended June 30, 2025 and 2024, but the specific line items and figures are not detailed within the provided text of the 6-K itself.
What is the primary purpose of the Management's Discussion and Analysis (MD&A) included in this filing?
The Interim MD&A for the Third Quarter Ended June 30, 2025, provides management's perspective on the company's financial condition and results of operations.
When is Bright Minds Biosciences' fiscal year end?
Bright Minds Biosciences' fiscal year ends on September 30.
What is the company's principal executive office address?
The company's principal executive office is located at 19 Vestry Street, New York, NY 10013.
Does Bright Minds Biosciences file annual reports under Form 20-F or Form 40-F?
Bright Minds Biosciences indicates it files annual reports under Form 20-F.
Filing Stats: 292 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2025-08-14 18:59:08
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 394KB
- exhibit99-2.htm (EX-99.2) — 167KB
- exhibit99-3.htm (EX-99.3) — 7KB
- exhibit99-4.htm (EX-99.4) — 7KB
- exhibit99-2x002.jpg (GRAPHIC) — 38KB
- exhibit99-2x003.jpg (GRAPHIC) — 39KB
- exhibit99-2x004.jpg (GRAPHIC) — 57KB
- 0001062993-25-014464.txt ( ) — 769KB
Management's Discussion and Analysis for the Third Quarter Ended June 30, 2025
Management's Discussion and Analysis for the Third Quarter Ended June 30, 2025 99.3 Certification of Interim Filings - CEO 99.4 Certification of Interim Filings - CFO SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BRIGHT MINDS BIOSCIENCES INC. /s/ Ryan Cheung __________________________ Ryan Cheung Chief Financial Officer Date: August 14, 2025